Evidence map›Paper›PMID 18979076›Full record

ReviewImmunologic research2009

Endocytosis as a mechanism of regulating natural killer cell function: unique endocytic and trafficking pathway for CD94/NKG2A.

Giovanna Peruzzi, Madhan Masilamani, Francisco Borrego, John E Coligan

Open access · greenAbstract readReview
In one paragraph

Review in Immunologic research, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.2field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 16 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Critical considerations for targeting colorectal liver metastases with nanotechnology.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2020
    Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Giovanna PeruzziReceptor Cell Biology Section, Laboratory of Immunogenetics, National Institute of Allergy and Infectious Diseases, NIH, Twinbrook II, Room 205, MS 8180 12441 Parklawn Drive, Rockville, MD 20852, USA.
Madhan Masilamani
Francisco Borrego
John E Coligan
National Institutes of Health · USIcahn School of Medicine at Mount Sinai · USNational Institute of Allergy and Infectious Diseases · US

Funding

Role of NKG2 Family Receptors in Regulating the Immune ResponseZ01AI000963 · NIAID · NIAID EXTRAMURAL ACTIVITIES · PI COLIGAN, JOHN E · 2006 to 2008
$1.7M
Intramural NIH HHS Z01 AI000963
6 · The paper itself

Abstract

Natural killer (NK) cells are lymphocytes generally recognized as sentinels of the innate immune system due to their inherent capacity to deal with diseased (stressed) cells, including malignant and infected. This ability to recognize many potentially pathogenic situations is due to the expression of a diverse panel of activation receptors. Because NK cell activation triggers an aggressive inflammatory response, it is important to have a means of throttling this response. Hence, NK cells also express a panel of inhibitory receptors that recognize ligands expressed by "normal" cells. Little or nothing is known about the endocytosis and trafficking of NK cell receptors, which are of great relevance to understanding how NK cells maintain the appropriate balance of activating and inhibitory receptors on their cell surface. In this review, we focus on the ITIM-containing inhibitory receptor CD94/NKG2A showing that it is endocytosed by a previously undescribed macropinocytic-like process that may be related to the maintenance of its surface expression.

Indexed as

AnimalsEndocytosisHumansImmunity, InnateKiller Cells, NaturalNK Cell Lectin-Like Receptor Subfamily CNK Cell Lectin-Like Receptor Subfamily DProtein TransportNK Cell Lectin-Like Receptor Subfamily CNK Cell Lectin-Like Receptor Subfamily D

Identifiers

PMID18979076
PMCPMC2752144
OpenAlexW2080415741

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.